Quantcast
Last updated on April 16, 2014 at 11:25 EDT

Latest Welichem Biotech Inc. Stories

2014-01-02 20:20:31

BURNABY, BC, Jan. 2, 2014 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI), announced today that Ryan B. Zeng has been appointed as a new director of the Company effective immediately. Mr. Zeng has been serving as a senior manager of T&T Supermarket in Richmond, British Columbia since 2008. He has extensive experience and knowledge in computer sciences, company operation and management from various industries including technology and supermarket companies over...

2013-10-10 00:20:38

VANCOUVER, Oct. 10, 2013 /CNW/ - Welichem Biotech Inc. ("Welichem" or the "Company", TSX.V: WBI) announces today the results of its substantial issuer bid, pursuant to which the Company offered to purchase for cancellation up to 23,529,411 of its issued and outstanding common shares ("Shares") at a purchase price of $0.85 per Share for an aggregate purchase price of up to $20 million (the "Offer"). The offer expired at 5:00 p.m. (Toronto time) on October 9, 2013. Based on the final...

2013-08-30 04:20:44

VANCOUVER, Aug. 30, 2013 /CNW/ - Welichem Biotech Inc. ("Welichem" or the "Company", TSX.V: WBI) announces that it is making a substantial issuer bid pursuant to which it will offer to purchase for cancellation up to 23,294,411 of its outstanding common shares ("Shares") at a purchase price of $0.85 per Share for an aggregate purchase price of up to $20 million (the "Offer"). The Offer is being made to provide its shareholders with an opportunity for liquidity, as trading on the TSX...

2013-03-28 20:21:48

VANCOUVER, March 28, 2013 /CNW/ - Welichem Biotech Inc. ("Welichem" or the "Company") (TSXV:WBI) announced today that it has entered into an asset purchase agreement (the "APA") to purchase the exclusive development and commercialization rights (the "Rights") to the novel anti-inflammatory agent, WBI-1001, in China, Taiwan, Macao and Hong Kong from Shenzhen Celestial Pharmaceuticals Ltd. and Beijing Wenfeng Tianji Pharmaceuticals Co., Ltd. (together, the "Vendors").  Upon entering...

2013-03-01 20:22:41

BURNABY, BC, March 1, 2013 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI), announced today that Mrs. Lijuan Pang has resigned as a director of the Company effective March 1, 2013. The Company has valued the contribution of Mrs. Pang as a director of the Company over the past one and half years and wishes her success in her future endeavours. About Welichem Biotech Inc. Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in...

2012-07-31 10:25:32

VANCOUVER, July 31, 2012 /CNW/ - Welichem Biotech Inc. ("Welichem" or the "Company" TSX.V: WBI) announces that Welichem and Stiefel, a GSK company, have completed the acquisition by Stiefel of the exclusive development and commercialization rights to the novel anti-inflammatory agent, WBI-1001, pursuant to the previously announced asset purchase agreement.  The shareholders of Welichem approved the agreement with Stiefel at a special meeting of the Company held on July 5, 2012....

2012-05-30 10:25:17

RESEARCH TRIANGLE PARK, N.C., May 30, 2012 /PRNewswire/ -- Stiefel, a GSK (NYSE:GSK) company, and Welichem Biotech, Inc. (WBI:CN), have entered into an agreement for the acquisition by Stiefel of exclusive development and commercialization rights to the novel anti-inflammatory agent, WBI-1001, in all territories outside of China, Taiwan, Macao and Hong Kong. WBI-1001 is currently in Phase II clinical development for the treatment of psoriasis and atopic dermatitis. The transaction is...

2012-05-30 10:25:03

VANCOUVER, May 30, 2012 /CNW/ - Stiefel, a GSK company, and Welichem Biotech Inc., have entered into  an agreement for the acquisition by Stiefel of exclusive development and commercialization rights to the novel anti-inflammatory agent, WBI-1001, in all territories in the world outside of China, Taiwan, Macao and Hong Kong.  WBI-1001 is currently in Phase II clinical development for the treatment of psoriasis and atopic dermatitis. Welichem will receive an initial payment...